A

$A

Agilent Technologies

Life sciences instruments, diagnostics, and applied chemical markets.

Healthcare
$175.34
-1.99 (-1.12%)
Day Range$174.61 - $180.16
Prev Close$177.33

A key facts as of November 14, 2026

Latest AI research report
Agilent (A): Valuation and Earnings Outlook (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Strong Buy (3 Strong Buy, 12 Buy, 7 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$174.29 mean (range $150.00 to $195.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
15 Buy / 7 Hold / 0 Sell
Price Target
$174.29
-0.6% downside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

NEUTRAL

Agilent (A): Valuation and Earnings Outlook

Agilent closed Friday, November 13, at $173.96, near its 52-week high, after a reported quarterly EPS beat. Analyst views are generally favorable, but the supplied mean target is close to the market price and valuation remains an important risk ahead of the November 23 earnings report.

Nov 14, 2026

A FAQ

What is StockAlpha's latest view on A?

StockAlpha's latest AI research report on Agilent Technologies (A), "Agilent (A): Valuation and Earnings Outlook", was published on November 14, 2026 and rates the overall sentiment as neutral. Agilent closed Friday, November 13, at $173.96, near its 52-week high, after a reported quarterly EPS beat. Analyst views are generally favorable, but the supplied mean target is close to the market price and valuation remains an important risk ahead of the November 23 earnings report.

When was the A research last updated?

The most recent A report was published on November 14, 2026.

What do analysts expect for A?

As of November 1, 2026, the analyst consensus on A is Strong Buy (3 Strong Buy, 12 Buy, 7 Hold, 0 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $174.29 mean (range $150.00 to $195.00).

Is this A research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring